

# **2025 withdrawal proposal for pharmlagen for the treatment of bee and wasp venom allergy (TA246)**

## **Consultation**

### **Topic areas**

- Pharmlagen for the treatment of bee and wasp venom allergy.

### **Withdrawal proposal**

We propose to withdraw the NICE technology appraisal (TA) guidance on [pharmlagen for the treatment of bee and wasp venom allergy](#) (TA246) in line with section 8.2.19 of the [NICE health technology evaluations manual](#).

### **Methods**

The withdrawal surveillance review process consisted of:

- Considering whether the conditions under which NICE should withdraw TA guidance as stated in section 8.2.19 of the [NICE health technology evaluations manual](#) are met.
- Considering the availability of NICE guidance and other UK guidance.
- Considering the implications of withdrawing the TA in terms of system impact; population impact; health inequalities; budget impact; and NICE organisational needs.

### **Basis for the withdrawal proposal**

Pharmlagen no longer has a marketing authorisation for the treatment of bee and wasp venom allergy in the UK.

### **Relevant NICE guidance**

This TA is not within scope of the [NICE guideline on anaphylaxis](#) (CG134).

## **Other relevant UK guidance**

There are no UK guidelines that currently recommend pharmalgen as it is being phased out and replaced by Alutard SQ.

## **System impact**

NICE system intelligence on drug usage indicates that pharmalgen is no longer used in the UK. The manufacturer confirmed that pharmalgen was phased out and the UK license withdrawn due to the introduction of a newer product for the treatment of bee and wasp venom allergy (Alutard SQ).

## **Population impact**

There is not anticipated to be any population impact of withdrawing this TA as the technology no longer has a UK marketing authorisation and therefore is not used in the NHS.

## **Health inequalities**

No health inequalities were identified with withdrawing this TA.

## **Budget impact**

No budget impact implications were identified with withdrawing this TA.

## **Overall proposal**

We propose to withdraw the NICE TA guidance on [pharmalgen for the treatment of bee and wasp venom allergy](#) (TA246) as it no longer has marketing authorisation in the UK.